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Aims: To explore the feasibility of detecting sex chromosome aneuploidies (SCAs) by means of gene copy
number quantification of short stature homeobox (SHOX), vesicle-associated membrane protein 7 (VAMP7),
and SRY in newborns.
Materials and Methods: Gene doses of SHOX, VAMP7, and SRY were determined by quantitative polymerase
chain reaction (qPCR) using DNA obtained from dried blood samples from newborns. Relative quantification
values were obtained. An aneuploidy profile was established according to cutoff values. Samples with ‡2 gene
doses (out of range) were reanalyzed, and those with aneuploidy profiles were confirmed by karyotyping.
Sensitivity, specificity, and positive and negative predictive values were obtained.
Results: A total of 10,033 samples were collected (4945 females and 5088 males). Of 244 (2.43%) samples with
‡2 gene doses that were retested, 20 cases were confirmed. The overall incidence of SCAs was 1 in 500 live
newborns. There were six cases of Turner syndrome (1/824), 3 cases of XXX (1/1648), 7 cases of Klinefelter
syndrome (1/726), and 4 cases of of XYY (1/1272). The sensitivity was 0.952 (95.24%), specificity of 0.975
(97.56%), positive predictive value of 0.909 (90.91%), and negative predictive value of 0.987 (98.77%).
Conclusions: Gene copy number analyses of VAMP7, SHOX, and SRY genes by qPCR from blood samples
spotted onto filter paper is a highly reliable method for the early detection of male and female SCAs.
Keywords: sex chromosome aneuploidies, early detection, molecular test, Turner syndrome, Klinefelter
syndrome
Introduction
Sex chromosome aneuploidies (SCAs) are numericalanomalies of the X or Y chromosomes, which are the
most frequent chromosomal aneuploidies in humans (Nielsen
and Wohlert, 1990). Klinefelter syndrome (KS) (47,XXY) is
the most common in men (1/500), and Turner syndrome (TS)
(45,X), with a prevalence of 1/2500, is the most common
monosomy (Nielsen and Wohlert, 1990). Such chromosomal
abnormalities lead to an increased mortality and morbidity
associated to a wide range of diseases (Berglund et al., 2019).
Clinical features of TS are short stature, webbed neck, and
ovarian dysfunction, leading to infertility, osteoporosis, car-
diovascular malformations, diabetes mellitus, and thyroid
autoimmune diseases. Patients will benefit from early diag-
nosis since administration of growth hormone could give
them the opportunity to reach a normal height and hormone
replacement therapy; however, many girls with TS are not
diagnosed until after 10 years old (Lee and Conway, 2014).
The clinical phenotype of KS patients is highly variable;
the most relevant clinical characteristics are: average height
5–7 cm greater than a man of the same age and race without
KS, hypergonadotrophic hypogonadism, and gynecomastia
in about one third of individuals. Most patients have small
testes and azoospermia, increased risk of breast cancer and
endocrine and autoimmune diseases, and a 25% chance of
developing osteoporosis (Grace, 2004; Gravholt et al., 2018).
Hormone replacement therapy with testosterone should
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initiate at the beginning of puberty to reach adequate hor-
monal levels to initiate virilization, improve libido, osteo-
porosis prevention, and increase muscle mass. Infertility is a
characteristic of KS patients; nevertheless, there are reports
of patients with low fertility (Groth et al., 2013).
SCAs are not associated with obvious features at birth;
therefore, only a small percentage of such disorders are
detected in four newborns, for example, 10% for KS and
30–50% for TS (Stochholm et al., 2006; Herlihy et al., 2011).
This may reduce the opportunity for early intervention, which
may improve the quality of life of affected individuals (Lee
and Conway, 2014).
There have been several efforts to detect SCAs using molec-
ular technologies at different stages of life. Schmidt et al. (2000)
reported a method for the prenatal diagnosis of somatic aneu-
ploidies and SCAs based on the gene copy number. Other reports
include the analysis by quantitative polymerase chain reaction
(qPCR) of different genes for the diagnosis of TS, such as the
androgen receptor (AR) gene (Rocha et al., 2010), dose-sensitive
sex reversal-adrenal hypoplasia congenital critical region on the
X chromosome gene 1 (DAX1), and the arylsulfatase E gene
(ARSE) (Rocha et al., 2005), and for the diagnosis of KS, such as
theAR and short stature homeobox (SHOX) genes (Ottesen et al.,
2007; Aksglaede et al., 2012). We have previously published, in
already diagnosed patients, that the identification of TS could be
done by means of quantifying copy number of SHOX and
VAMP7 (vesicle-associated membrane protein 7) pseudoauto-
somal genes together with the SRY (Ibarra-Ramirez et al., 2015).
The use of genetic markers for SCA diagnosis has been
reported by several authors, either in already diagnosed pa-
tients or through next generation sequencing for prenatal di-
agnosis (Porreco et al., 2014; Zhang et al., 2017). In a previous
report, Yoshimi et al. used fragile X-related epigenetic ele-
ment 2, SRY, and FMR1 CGG repeat analysis, applied for
fragile X syndrome screening in newborns, in the screening for
SCA in 257 participants, aged between 19 and 69 years, in
control males and females and SCA individuals, obtaining a
high sensitivity and specificity (Inaba et al., 2013).
Several authors (Rocha et al., 2005; Watson et al., 2006;
Rivkees et al., 2011) have reported high correlations in the
diagnosis of SCAswithmolecular techniqueswhen comparing
to the gold standard method (i.e., karyotyping). Nevertheless,
these were performed in patients who already had a diagnosis
of SCA. In another study, Correa et al., developed amethod for
neonatal detection of TS using ARSE andMAGEH1 gene dose
quantification, which was tested in 996 newborns whose pe-
ripheral blood was collected and stored on filter paper, re-
porting a 95% detection sensitivity (Correa et al., 2014).
In the present study, we explore the feasibility of detecting
SCAs by means of gene copy number quantification of
SHOX, VAMP7, and SRY using dried blood samples from
newborns spotted onto filter paper.
Materials and Methods
Patient data
A prospective blind study was performed at two hospitals
in Nuevo Leo´n, Me´xico from May 2014 through July 2015.
All live-born infants were eligible to participate, except for
those that were transfused at birth. The protocol was ap-
proved by the Ethics Committee of the Facultad de Medicina
y Hospital Universitario of the Universidad Autonoma de
Nuevo Leon (registration no. GN13-002). Informed consent
was obtained from parents or guardians, and a questionnaire
addressing demographic data of the mother and neonates was
completed for all participants.
Specimen collection
Blood samples were obtained by heel puncture in neonates
at 24 h after birth, placed directly onto FTA Elute Micro
Cards (no. WB120410; Whatman; GE Healthcare, Buck-
inghamshire, UK), and transported to the laboratory 2–3 days
after collection. The cards were stored at room temperature in
bags containing desiccants until further processing.
Inclusion criteria: only full term, apparently healthy neo-
nates at 24 h postnatal life were included.
Exclusion criteria: presence of congenital defects or had
received transfusions.
DNA extraction
DNA from FTA Elute cards was extracted according to the
manufacturer’s instructions, with the following modifica-
tions: three 1-mm disks from each sample were placed in a
single well of a multiwell plate; 350mL of Milli-Q water was
added to each well and vortexed for 10 s. After a brief cen-
trifugation, 45 mL containing the eluted DNA was transferred
to new tube. Samples were incubated at 95C for 20min. The
DNA from the samples was quantified using a NanoDrop
8000 spectrophotometer (Thermo Scientific, Wilmington,
DE), and DNA concentration was adjusted to 10 ng/mL.
Determination of gene copy number by qPCR
Copy number quantification assays were performed using
TaqMan probes (Applied Biosystems, Foster City, CA) fol-
lowing the manufacturer’s instructions. The reference gene
(RNaseP) was detected using a VIC-labeled TaqMan probe
(catalog no. 4403328), whereas all other genes were detected
using a 6-FAM-labeled TaqMan probe (Table 1). Real-time
PCR was performed using a StepOnePlus Real-Time PCR
System (Applied Biosystems), with 4mL of 2·TaqMan
GenotypingMasterMix, 0.5mL of each TaqMan probe (20· ),
0.5mL of the reference gene probe, and 5mL of 20·DNA to a
final volume of 10mL in a MicroAmp Fast Optical 96-Well
Reaction Plate (Applied Biosystems). Amplification was per-
formed under the following conditions: 95C for 10min, fol-
lowed by 45 cycles at 95C for 20 s, and 60C for 1min.
For normalization, the internal control gene RNaseP was
amplified in parallel in the same well with the target gene under
identical thermocycling conditions. The correlation coefficient
between the cycle threshold (CT) and the DNA template con-
centration for each TaqMan assay was calculated by regression
analysis. The amplification efficiency was calculated using the
following formula: efficiency=-1+10(-1/slope).
Establishment of cutoff values
In this study, an analysis of global simulation based on the
Monte Carlo method was designed and used. Considering the
frequency of SCAs reported in several populations (1/400)
(Nielsen and Wohlert, 1990), it was assumed that the prob-
ability of a positive sample is one in every five plates;
therefore, every sample in each plate was used as a reference
control for the other samples of each pool.
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Briefly, data for each of the three target genes (SHOX,
VAMP7, and SRY) were imported in plain-text format. For
each batch, each sample was used in turn as a reference
sample. Relative quantification (RQ) values were obtained
using the delta-delta CT (DDCT) method (Livak and
Schmittgen, 2001). Each sample was classified as ‘‘loss,’’
‘‘gain,’’ or ‘‘normal.’’ RQ ‡1.3 was considered a ‘‘gain,’’
whereas RQ £0.7 constituted a ‘‘loss,’’ and intermediate
values were counted as ‘‘normal.’’ Those specimens with two
or more genes with RQ values out of range (gain or loss) were
reanalyzed in the same sample (second analysis, Fig. 1).
An SCA profile was previously developed (Campos-
Acevedo et al., 2016), and cases were classified as follows: in
female neonates, when SHOX and VAMP7 RQ values were
both above 1.3, possible XXX syndrome was indicated, and
when the RQ values were below 0.7, this indicated TS
(X monosomy). In male children, when SHOX and VAMP7
RQ values were above 1.3 with normal SRY, this was sug-
gestive of KS (XXY), and when elevated RQ values of SHOX
and VAMP7 were associated with increased values of SRY,
XYY syndrome was suspected (Supplementary Data).
Table 1. The Primers and Probes
Used in This Study
Genes Sequences and assay ID
SHOX
Primer F 5¢-GAGACCAGTAATTGCACCAGACA-3¢
Primer R 5¢-GCTGTTATTTACGCCTTTCCATTGG-3¢
Probe 5¢-FAM-CCAGCCCCCCATGCGCT NFQ-3¢
VAMP7
Primer F 5¢-AGAGAACAAGGAGTTAAAAGCAA
TCCA-3¢
Primer R 5¢-AGTGAGAAGAGGGTTGAAGAGACT-3¢
Probe 5¢-FAM-CCTTTCACATACTGACAGATGG
TATCT NFQ-3¢
SRY Hs01079437
RNAsa P PN. 4403328
SHOX, short stature homeobox; VAMP7, vesicle-associated
membrane protein 7.
FIG. 1. Study algorithm. A study algorithm was established to determine the profiles of SCAs according to the values
obtained from the RQ of each of the analyzed genes (SHOX, VAMP7, and SRY). RQ, relative quantification; SCAs, sex
chromosome aneuploidies; SHOX, short stature homeobox; VAMP7, vesicle-associated membrane protein 7.
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Samples with results suggestive of an SCA after the second
analysis were selected and the patients located for clinical
evaluation and blood sampling to perform a karyotype to
corroborate the diagnosis.
Quality control
Samples from patients with a confirmed diagnosis of SCA
were included as positive controls. To identify false negative
samples, a randomly selected subset of samples, from those
that only showed one gene dose out of the normal range
values, were retested. In addition, a subset from those that
showed two or more genes out of range but without SCA
profile was localized for karyotype.
Statistical analysis
The incidence of all SCAs and the incidence for each
separate disorder were calculated.
The ability of the test (SCA profile established according
to the reference cutoff values used) to identify true positives
and negatives in a data set was measured by sensitivity and
specificity as follows: sensitivity =TP/(TP + FN) and speci-
ficity =TN/(TN + FP) where FN was the false negative and
FP was the false positive. MedCalc Statistical Software
version 16.4.3 (MedCalc Software bvba, Ostend, Belgium,
2016) and IBM Corp. Released 2011. IBM SPSS Statistics
for Windows, Version 20.0. Armonk, NY: IBM Corp.
Karyotype analysis
Peripheral venous blood (2–4mL) from each newborn
with a result that showed an aneuploidy profile was collected
in a tube containing heparin for G banded karyotyping
(30 metaphases) (Arsham et al., 2017).
Results
A total of 10,033 samples were analyzed, of which 4945
(49%) were from female newborns, and 5088 (51%) were
male (distribution is shown in Fig. 2). From these, only 244
specimens (2.4%) had ‡2 gene doses out of range and were
retested on the same sample, by triplicate. After retesting, 25
samples showed the SCA profile established (9 female and 16
male neonates); from these, only 22 patients accepted follow-
up study and clinical evaluation. Twenty cases were con-
firmed as SCAs by karyotyping, and two resulted with normal
karyotype and were considered false positive cases (Fig. 3).
Table 2 shows the RQ values and karyotype reports. Nine
female newborns resulted in abnormal karyotypes: 6 were
confirmed as TS: 2 complete monosomies (45,X) and 4
mosaic: 45,X/47,XXX (1); 46 X, mar/46, XX (1); and
45,X/46,XX (2); the 3 other cases were X polysomies. From
male samples, 16 showed an SCA profile, 9 were suggestive
of KS, from which only 7 were confirmed by karyotype be-
cause 2 cases were lost in the follow-up; the other 7 samples
showed an XYY syndrome profile, although confirmation
was obtained only in 4 cases since in 2 cases karyotypes were
normal (these were considered false positive) and, in one
case, the parents refused to continue with the study.
One case with no SCA profile and RQ values of SHOX
(0.789) and VAMP7 (0.794) in normal range but with an SRY
(0.363) classified as loss gave us the suspicion of TS mosa-
icism. At clinical examination, the patient had a male phe-
notype, and the karyotype confirmed a mosaic of Turner
(45,X/46,XY). In this case, a diagnosis of gonadal dysgenesis
was established. This was considered as a false negative.
Quality control: All included positive controls showed a
gene dose of VAMP7, SHOX, and SRY with an SCA profile
that corroborated the reproducibility of the test by triplicate
(data not shown). From those that only had one gene out of
cutoff values (9789), a total of 439 samples were randomly
chosen and retested, obtaining the same results. Eighty sam-
ples out of the 244 (32.7%), with abnormal RQ but not SCA
profile after second test, were randomly selected and children
localized for karyotyping, which all resulted as normal.
The overall frequency of SCAs was 1:500. TS was diag-
nosed in 1:824 female live newborns, and X polysomy was
diagnosed in 1:1648 female live newborns, while KS and
XYY syndromes were diagnosed in 1:726 and 1:1272 male
live newborns, respectively. Sensitivity and specificity of the
SCA test, using the established profile and the cutoff values
obtained, were 95.24% and 97.56%, respectively, and posi-
tive predictive value (PPV) and negative predictive value
(NPV) were 90.91% and 98.77%, respectively.
All newborns diagnosed with SCA had normal height and
weight at birth. Only two patients with TS, with regular
monosomy, had clinical data suggestive of the disease, such
as heart defects (aortic coarctation and ventricular septal
defect) and hyperpigmented macules. Two patients with
XYY syndrome had micropenis and cryptorchidism. Never-
theless, only one case had been previously diagnosed before
we did the evaluation and karyotype, and the others were
diagnosed until they were summoned to our clinic for eval-
uation due to their abnormal screening test results.
Discussion
Several authors agree in the necessity of an early diagnosis
of SCAs, particularly TS (Sarikaya, 2017) and KS (Herlihy
andMcLachlan, 2015), due to the increased knowledge about
FIG. 2. Scatter plot of RQ values of all samples, showing
the distribution of female (blue circles) and male (squares)
newborns, represented along the three axes according to the
cutoff values. Samples that were out of range for the SRY
gene are shown in red. Color images are available online.
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FIG. 3. Result overview. The screening results of 10,033 newborns.
Table 2. Results from Patients Detected by Neonatal Screening. Relative Quantification Values
of the Three Genes Analyzed by Quantitative Polymerase Chain Reaction Showing the Profile
of Sex Chromosome Aneuploidies and G Karyotype Analysis Results
from Patients Detected by Neonatal Screening
Case
SHOX VAMP7 SRY
KaryotypeRQ value RQ value RQ value
1 0.369 0.426 0 45,X
2 0.48 0.55 0 45,X
3 0.59 0.616 0 45,X[44]/47,XXX[6]
4 0.707 0.62 0 mos45,X[9]/46,XX[21]
5 0.69 0.61 0 mos45,X[13]/46,XX[17]
6 0.487 0.624 0 mos45,X[22]/47,X,+mar,+mar[6]/46,X+mar[2]
7 1.435 1.32 0 47, XXX
8 1.387 1.548 0 47,XXX
9 1.313 1.384 0 47,XXX
10 1.326 1.548 1.69 47,XYY
11 1.358 1.673 1.561 47,XYY
12 1.545 1.681 1.588 47,XYY
13 1.406 1.444 1.715 47,XYY
14 1.511 1.685 1.527 46,XYa
15 1.8 1.55 2.07 46,XYa
16 1.227 1.431 1.727 ND
17 1.313 1.559 1.03 47,XXY
18 1.319 1.453 0.989 47,XXY
19 1.466 1.525 1.019 47,XXY
20 1.458 1.571 0.842 47,XXY
21 1.418 1.395 0.903 47,XXY
22 1.353 1.343 0.988 47,XXY
23 1.353 1.343 0.988 47,XXY
24 1.405 1.627 1.114 ND
25 1.453 1.526 0.863 ND
In one case, the parents refused to continue in the study (case 16), and two cases were lost to follow-up (cases 24 and 25); thus, karyotype
analysis could not be performed.
aCases considered false positive (cases 14 and 15).
ND, no data; RQ, relative quantification.
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the treatment options that will benefit these patients. Even
more, recently Berglun et al. (2019) reported that as SCAs are
associated with increased morbidity and mortality and
learning and/or behavioral disabilities, so the early diagnosis
will provide better overall long-term outcome by providing
an opportunity for timely intervention.
The pseudoautosomal regions (PAR1 and PAR2) are short
regions of homology between the mammalian X and Y chro-
mosomes. The PARs behave similar to an autosome and re-
combine during meiosis. In a previous study, we designed a
methodology by means of quantification of gene copy number
of SHOX (PAR1) and VAMP7 genes (PAR2) in both chromo-
somes and the SRY gene (only on the Y chromosome) to es-
tablish amolecular test for the diagnosis of SCAs (Porreco et al.,
2014). This method was used in the present study allowing the
identification of 20 patients with an SCA in male and female
neonates (Turner, Klinefelter, XYY, and XXX syndromes).
The overall incidence of SCA cases found in this population
from northeast Mexico was 1:500, which is similar to those
reported in other populations, although the incidence ofTSwas
1:824, which is higher than that reported in the literature
(1:2000–1:3000) (Nielsen and Wohlert, 1990). Contrary to
previously reported data, where regular monosomy is the most
common cause of this syndrome (Sybert andMcCauley, 2004),
the chromosomevariant distribution ofTS in our study showed
thatmost patientsweremosaics, and only 33%hadmonosomy.
However, these conflicting results could reflect the under-
diagnosis of this disorder in patients with mosaicism because
they show a less distinctive phenotype at birth (Koeberl et al.,
1995). Our data are according to Tuke et al. who performed a
study in adult women using single nucleotide polymorphism
array technic and reported an overall prevalence ofTurner of 1 in
1136 with a distribution of 1 in 8333 nonmosaic 45,X and 1 in
1315 for mosaic 45,X/46,XX, indicating that most mosaics are
not detected maybe due to reduced penetrance. It is important to
mention thatwith ourmethodwe detected other type ofmosaics,
whichmayexplain thehigher prevalence rate (Tuke et al., 2019).
We diagnosed three patients with X polysomy, which is
one of the least diagnosed SCAs due to its variable phenotype
(Otter et al., 2010; Tartaglia et al., 2010). The incidence of
this disease in the present study was 1:1648, which was
somewhat lower than reported previously (1:1000) (Nielsen
and Wohlert, 1990).
KS was confirmed in seven patients, with an incidence of
1:726 newborn males, similar to that reported in the literature
(Nielsen and Wohlert, 1990). These patients were not diag-
nosed at birth. KS is very difficult to diagnose because pa-
tients present only minor dysmorphias and normal height
(Ratcliffe, 1999). Two cases with a KS profile in the newborn
screening were lost in the follow-up and could not be con-
firmed by karyotyping; thus, these were not assigned as false
positive or false negative.
The incidence observed in patients with XYY syndrome
was 1:1272, which agrees with previously reported data
(1:1000) (Nielsen andWohlert, 1990). XYY syndrome and X
polysomy are both underdiagnosed due to phenotype vari-
ability (Ratcliffe, 1999); nevertheless, some reports suggest
that intellectual impairment and behavior problems are as-
sociated with these diseases (Cordeiro et al., 2012; Ulgiati
et al., 2013); thus, earlier detection could provide an oppor-
tunity for better treatment of such complications (Lalatta
et al., 2012).
In one case, a patient who did not show a SCA profile but
with a low RQ value of SRY was clinically evaluated, and a
karyotyping was performed. A diagnose of gonadal dysgenesis
was done due to the male phenotype of the patient and the
karyotype result (45,X/46,XY). In this case, it was possible to
give a close follow-up andmedicalmanagement. The incidence
of this disorder is 1:15,000 (Muller et al., 1999) in newborns; in
the present study, we found 1 case in 10,000 newborns.
Nevertheless, this case was considered false negative. Two
cases that initially showed the XYY profile revealed a normal
karyotype. These were considered as false positive cases.
For the diagnosis of SCA, the correlation of the cases de-
tected with the method presented here with karyotyping was
90%. Since only 10–30% of SCAs are detected at birth
(Stochholm et al., 2006; Herlihy et al., 2011), the detection
rate of these pathologies in newborns with our methodology
will significantly increase, allowing the opportunity for
prompt and adequate intervention. Sensitivity and specificity
of the SCA profile were 95.24% and 97.56%, respectively,
and PPV (90.91%) and NPV (98.77%).
Compared to other technics such as multiplex ligation-
dependent probe amplification (MLPA), our method is less
expensive and less time consuming; besides, MLPA is not
suitable for use in high throughput dry blood spot screening
method. The methodology used in the present is an important
tool because it is quick and easy to screen for sex chromosome
aneuploidies, as the karyotype is time consuming and it can
only be performed in specialized laboratories of cytogenetics.
To our knowledge, this is the first large-scale study that
used a molecular approach for the early detection of SCA,
which is capable of detecting mosaics.
Conclusions
Gene copy number analysis of VAMP7, SHOX, and SRY
genes by qPCR in blood samples spotted onto filter paper is a
good method for the early detection of male and female SCAs.
Acknowledgments
The authors thank the volunteers and staff from the Hos-
pital Universitario Jose´ E. Gonza´lez, Universidad Auto´noma
de Nuevo Leo´n (UANL), and Hospital Regional Materno
Infantil from the Nuevo Leon Health Services, as well as the
personnel of the Department of Genetics from the School of
Medicine (UANL).
Author Disclosure Statement
No competing financial interests exist.
Funding Information
This study was supported by the Consejo Nacional de
Ciencia y Tecnologı´a (CONACyT) CLAVE SALUD (2013-
1-202628).
Supplementary Material
Supplementary Data
References
Aksglaede L, Garn ID, Hollegaard MV, et al. (2012) Detection
of increased gene copy number in DNA from dried blood spot
6 IBARRA-RAMI´REZ ET AL.
samples allows efficient screening for Klinefelter syndrome.
Acta Paediatr 101:e561–e563.
Arsham MS, Barch MJ, Lawce HJ; Association of Genetic
Technologists (2017) The AGT Cytogenetics Laboratory
Manual. John Wiley & Sons, Inc., Hoboken, NJ.
Berglund A, Viuff MH, Skakkebaek A, et al. (2019) Changes in
the cohort composition of turner syndrome and severe non-
diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a
nationwide cohort study. Orphanet J Rare Dis 14:16.
Campos-Acevedo LD, Ibarra-Ramirez M, Lugo-Trampe JJ,
et al. (2016) Dosage of sex chromosomal genes in blood
deposited on filter paper for neonatal screening of sex chro-
mosome aneuploidy. Genet Test Mol Biomarkers 20:786–
790.
Cordeiro L, Tartaglia N, Roeltgen D, et al. (2012) Social def-
icits in male children and adolescents with sex chromosome
aneuploidy: a comparison of XXY, XYY, and XXYY syn-
dromes. Res Dev Disabil 33:1254–1263.
Correa SC, Rocha MN, Richeti F, et al. (2014) Neonatal de-
tection of Turner syndrome by real-time PCR gene quantifi-
cation of the ARSE and MAGEH1 genes. Genet Mol Res 13:
9068–9076.
Grace RJ (2004) Klinefelter’s syndrome: a late diagnosis.
Lancet 364:284.
Gravholt CH, Chang S, Wallentin M, et al. (2018) Klinefelter
syndrome: integrating genetics, neuropsychology, and endo-
crinology. Endocr Rev 39:389–423.
Groth KA, Skakkebaek A, Host C, et al. (2013) Clinical review:
klinefelter syndrome—a clinical update. J Clin Endocrinol
Metab 98:20–30.
Herlihy AS, Gillam L, Halliday JL, et al. (2011) Postnatal
screening for Klinefelter syndrome: is there a rationale? Acta
Paediatr 100:923–933.
Herlihy AS, McLachlan RI (2015) Screening for Klinefelter
syndrome. Curr Opin Endocrinol Diabetes Obes 22:224–229.
Ibarra-Ramirez M, Zamudio-Osuna MJ, Campos-Acevedo LD,
et al. (2015) Detection of Turner syndrome by quantitative
PCR of SHOX and VAMP7 genes. Genet Test Mol Bio-
markers 19:88–92.
Inaba Y, Herlihy AS, Schwartz CE, et al. (2013) Fragile
X-related element 2 methylation analysis may provide a
suitable option for inclusion of fragile X syndrome and/or sex
chromosome aneuploidy into newborn screening: a technical
validation study. Genet Med 15:290–298.
Koeberl DD, McGillivray B, Sybert VP (1995) Prenatal diag-
nosis of 45,X/46,XX mosaicism and 45,X: implications for
postnatal outcome. Am J Hum Genet 57:661–666.
Lalatta F, Folliero E, Cavallari U, et al. (2012) Early mani-
festations in a cohort of children prenatally diagnosed with
47,XYY. Role of multidisciplinary counseling for parental
guidance and prevention of aggressive behavior. Ital J Pediatr
38:52.
Lee MC, Conway GS (2014) Turner’s syndrome: challenges of
late diagnosis. Lancet Diabetes Endocrinol 2:333–338.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene
expression data using real-time quantitative PCR and the
2(-Delta Delta C(T)) Method. Methods 25:402–408.
Muller J, Ritzen EM, Ivarsson SA, et al. (1999) Management of
males with 45,X/46,XY gonadal dysgenesis. Horm Res 52:
11–14.
Nielsen J, Wohlert M (1990) Sex chromosome abnormalities
found among 34,910 newborn children: results from a 13-year
incidence study in Arhus, Denmark. Birth Defects Orig Artic
Ser 26:209–223.
Otter M, Schrander-Stumpel CT, Curfs LM (2010) Triple X
syndrome: a review of the literature. Eur J Hum Genet 18:
265–271.
Ottesen AM, Garn ID, Aksglaede L, et al. (2007) A simple
screening method for detection of Klinefelter syndrome and
other X-chromosome aneuploidies based on copy number of
the androgen receptor gene. Mol Hum Reprod 13:745–750.
Porreco RP, Garite TJ, Maurel K, et al. (2014) Noninvasive
prenatal screening for fetal trisomies 21, 18, 13 and the
common sex chromosome aneuploidies from maternal blood
using massively parallel genomic sequencing of DNA.
Am J Obstet Gynecol 211:365.e1–365.e12.
Ratcliffe S (1999) Long-term outcome in children of sex
chromosome abnormalities. Arch Dis Child 80:192–195.
Rivkees SA, Hager K, Hosono S, et al. (2011) A highly sen-
sitive, high-throughput assay for the detection of Turner
syndrome. J Clin Endocrinol Metab 96:699–705.
Rocha MN, Longui CA, Kochi C, et al. (2010) Applicability of
real-time PCR methodology in the neonatal detection of
Turner syndrome. Horm Metab Res 42:677–681.
Rocha MN, Melo MR, Longui CA, et al. (2005) A three-step
molecular protocol employing DNA obtained from dried
blood spots for neonatal screening for 45,X Turner syndrome.
Genet Mol Res 4:749–754.
Sarikaya E (2017) Is it time to start newborn screening for
Turner syndrome? JSM Genet Genomics 4:1023.
Schmidt W, Jenderny J, Hecher K, et al. (2000) Detection of
aneuploidy in chromosomes X, Y, 13, 18 and 21 by QF-PCR in
662 selected pregnancies at risk. Mol Hum Reprod 6:855–860.
Stochholm K, Juul S, Juel K, et al. (2006) Prevalence, inci-
dence, diagnostic delay, and mortality in Turner syndrome.
J Clin Endocrinol Metab 91:3897–3902.
Sybert VP, McCauley E (2004) Turner’s syndrome. N Engl J
Med 351:1227–1238.
Tartaglia NR, Howell S, Sutherland A, et al. (2010) A review of
trisomy X (47,XXX). Orphanet J Rare Dis 5:8.
Tuke MA, Ruth KS, Wood AR, et al. (2019) Mosaic Turner
syndrome shows reduced penetrance in an adult population
study. Genet Med 21:877–886.
Ulgiati F, Nicita F, Papetti L, et al. (2013) Posterior fossa
malformations and sex chromosomes anomalies. Report of a
case with XYY syndrome and overview of known associa-
tions. Eur J Pediatr 172:1267–1270.
Watson M, Mann M, Rinaldo P, et al. (2006) Newborn
screening: toward a uniform screening panel and system.
Genet Med 8:1S–252S.
Zhang B, Lu BY, Yu B, et al. (2017) Noninvasive prenatal
screening for fetal common sex chromosome aneuploidies
from maternal blood. J Int Med Res 45:621–630.
Address correspondence to:
Laura Elia Martı´nez-de-Villarreal, MD, PhD
Departamento de Gene´tica
Facultad de Medicina y Hospital
Universitario Jose´ E. Gonza´lez
Universidad Auto´noma de Nuevo Leo´n (UANL)
Avenida Gonzalitos s/n cruce con Avenida Madero,
Colonia Mitras Centro
Monterrey CP 64460
Nuevo Leo´n
Me´xico
E-mail: laelmar@yahoo.com.mx
DETERMINATION OF SEXUAL ANEUPLOIDIES BY QPCR 7
